Cronos Group's Q3 2021 saw a significant increase in consolidated net revenue, driven by growth in the adult-use market in Canada, increased sales in the Israeli medical cannabis market, and increased sales in the U.S. segment. The company is realigning its business to focus on brands, centralizing functions, and prioritizing investments in innovation.
Consolidated net revenue increased by 80% compared to Q3 2020.
Launched Cronos Group's first cultured cannabinoid gummy and vape products under Spinach FEELZ™ brand.
Spinach® held a double-digit market share in the gummies category in Canada.
Strategic realignment is expected to deliver $20 to $25 million in savings across operating expense categories in 2022.
The overall strategic realignment initiative is expected to deliver $20 to $25 million in initially identified savings across operating expense categories in 2022, primarily driven by savings in sales and marketing, general and administrative, and research and development.
Visualization of income flow from segment revenue to net income